HDFC Life Insurance

Emkay® Your success is our success

Stable performance and outlook

Life Insurance > Result Update > April 18, 2025

CMP (Rs): 720 | TP (Rs): 775

HDFCLIFE reported an overall steady performance in growth (Retail APE YoY growth – FY25: 18%; Q4FY25: 9.7%) and profitability (FY25 VNB margin: 25.6%; VNB growth: 13% YoY) despite the headwinds from new surrender regulation implementation and decline in the MFI-linked Credit Life segment. Notwithstanding the intermittent short-term volatilities owing to the challenging macro environment and regulatory landscape changes, the management remains confident of doubling key performance metrics over 4 years – to help achieve this, it continues to invest in building capabilities and driving innovation. To account for the Q4 developments and future guidance, we marginally tweak our FY26-27 estimates which leads to a broadly unchanged (ie around -/+1%) VNB and EV. We reiterate BUY on the stock, with unchanged Mar-26E TP of Rs775 (implying FY27E P/EV: 2.2x).

Satisfactory APE growth and healthy VNB margin delivery

HDFC Life delivered a steady performance in FY25, with 16.5% APE growth at Rs154.8bn (Emkay: Rs156.8bn) and VNB margin at 25.6% vs our estimate of 25%. The company clocked in better-than-industry retail APE growth of 18% in FY25. For Q4FY25, APE grew 9.7% YoY and was 3.8% lower than our estimate, whereas VNB margin at 25.9% was better than our estimate of 25%. Driven by better margin delivery and offset by lower-than-expected APE growth, VNB for FY25 at Rs39.6bn (+13.2% YoY) was 1.7% higher than our estimate, while Q4FY25 VNB grew 11.5% and was 2.1% higher than our estimate. FY25 Embedded Value at Rs552.4bn grew 16.4% YoY, in line with our estimate. For FY25, PAT at Rs18bn grew 15% YoY and was 1.5% higher than our estimate, while Q4FY25 PAT at Rs4.8bn (+15.8% YoY) was higher than our estimate of Rs4.4bn.

The management remains confident of doubling key metrics every four years

Driven by its strong brand, distribution, and execution capabilities, HDFC Life has doubled its key metrics over FY21-25. While FY25 saw a host of challenges, including implementation of the new surrender regulations and slowdown in the credit protection business driven by a slowdown in MFI disbursals, the company reported a satisfactory better-than-industry APE growth while delivering healthy margins. Though the short-term environment remains challenging given the volatile macro-economic conditions and regulatory shifts, the management remains confident about its ability to double the key metrics over the next four years. Going forward, the management expects the protection segment to continue tracking the growth trajectory, while it believes non-par products should see better growth given the conducive interest rate environment. Further, the management continues to address the whitespaces driven by product innovation, aiding APE growth going forward. While the management continues to invest in building capabilities and driving innovation, VNB margins are likely to remain range-bound.

We reiterate BUY with unchanged Mar-26E TP of Rs775

To reflect the Q4 developments, we tweak our FY26-27 estimates which results in a \sim 3% APE cut, while a 40-50bps rise in VNB margin is causing a \sim 1% cut in VNB. We introduce FY28 estimates. Given HDFC Life's strong brand, distribution strength, and product innovation, we retain BUY and Mar-26E TP of Rs775, implying FY27E P/EV of 2.2x.

HDFC Life Insurance: Financial Snapshot (Standalone)									
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E				
GWP	630,765	710,449	823,820	956,744	1,112,486				
APE	132,910	154,790	178,391	206,410	238,885				
VNB	35,010	39,620	45,708	53,407	62,300				
VNB margin (%)	26.3	25.6	25.6	25.9	26.1				
APE growth (%)	(0.3)	16.5	15.2	15.7	15.7				
VNB growth (%)	(4.7)	13.2	15.4	16.8	16.7				
Adj. EPS (Rs)	7.4	8.5	9.7	11.0	12.8				
EV	474,690	554,310	642,086	742,582	857,331				
EVOP	69,210	79,220	91,495	104,923	120,159				
Op. RoEV (%)	17.5	16.7	16.5	16.3	16.2				
EVPS (INR)	220.7	257.5	298.2	344.9	398.2				
P/EV (x)	3.3	2.8	2.4	2.1	1.8				
P/EVOP (x)	22.2	19.4	16.8	14.7	12.8				

Source: Company, Emkay Research

Target Price – 12M	Mar-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	7.6

Stock Data	HDFCLIFE IN
52-week High (Rs)	761
52-week Low (Rs)	511
Shares outstanding (mn)	2,153.0
Market-cap (Rs bn)	1,550
Market-cap (USD mn)	18,158
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	2,104.7
ADTV-3M (USD mn)	24.7
Free float (%)	49.6
Nifty-50	23,851.7
INR/USD	85.4
Shareholding, Dec-24	
Promoters (%)	50.3
FPIs/MFs (%)	25.1/13.7

Price Performance							
(%)	1M	3M	12M				
Absolute	14.3	12.1	19.1				
Rel. to Nifty	7.9	9.1	10.6				

1-Year share price trend (Rs)



Avinash Singh avinash.singh@emkayglobal.com +91-22-66121327

Exhibit 1: HDFCLIFE - FY25/Q4FY25 Financial Result summary

(Rs bn)	FY25	FY24	YoY %	FY25	Var %	Q4FY25	Q4FY24	YoY %	Q4FY25E	% Var
APE	154.8	132.9	16.5	156.8	-1.3	51.9	47.3	9.7	53.9	-3.8
o/w Savings	137.5	115.2	19.3			47.9	42.5	12.8		
o/w Protection	17.3	17.7	-1.9			4.0	4.8	-17.5		
Protection APE (% of total APE)	11.2	13.3	-2.1ppts			7.6	10.1	-2.5ppts		7.6ppts
Value of New Business	39.6	35.0	13.2	39.3	0.7	13.8	12.3	11.5	13.5	2.1
New Business Margin (%)	25.6	26.3	-0.7ppts	25.1	0.5ppts	26.5	26.1	0.4ppts	25.0	1.5ppts
Embedded Value	552.4	474.7	16.4	551.7	0.1					
EV Operating Profit	79.2	69.2	14.5							
Operating RoEV (%)	16.7	17.5	-0.8ppts							
New Business Premium (NBP)	333.7	296.3	1.9	329.6		109.7	95.3	15.1		
Renewal premium	376.8	334.5	17.6	378.7		130.6	114.1	14.5		
Gross written premium	710.4	630.8	9.6	708.4		240.3	209.4	14.8		
PAT	18.0	15.7	14.9	17.7	1.5	4.8	4.1	15.8	4.4	7.5
AUM	3,363	2,922	15.1	3,361	0.0					
Solvency ratio (%)	194	187	7.0ppts							

Source: Company, Emkay Research

Exhibit 2: Appraisal methodology-based valuation for HDFC Life

Parameter (Rs bn)	Value
FY25E-40E APE CAGR	10.9%
FY25E-40E VNB CAGR	10.9%
Terminal growth rate	5.0%
Cost of Equity	13.0%
FY26 EV	642
Present value of future VNB	1,059
Appraisal Value - Mar-26E	1,693
Share count (mn)	2,153
Appraisal value per share - Mar-26E (Rs)	786
Target Price - Mar-26E (Rs)	775

Source: Company, Emkay Research

Exhibit 3: Implied valuation multiples for HDFC Life

Target price multiple on FY27 estimates	Rs775
P/EV	2.2x
RoEV (%)	16.3
P/EVOP	15.7x
Implied FY27E VNB multiple	19.2x

Current price multiple on FY27 estimates	Rs720
P/EV	2.1x
RoEV (%)	16.3
P/EVOP	14.6x
Implied FY27E VNB multiple	17.0x

Source: Company, Emkay Research


Exhibit 4: Changes in estimates

(Rs bn)		FY26E			FY27E			FY28E	
	Old	Revised	% Change	Old	Revised	% Change	Old	Revised	% Change
APE	183.4	178.4	-2.7	212.1	206.4	-2.7	NA	238.9	NM
VNB	46.2	45.7	-1.2	53.8	53.4	-0.7	NA	62.3	NM
VNB Margin (%)	25.2	25.6	0.4ppts	25.4	25.9	0.5ppts	NA	26.1	NM
EVOP	90.2	91.5	1.4	103.1	104.9	1.8	NA	120.2	NM
EV	638.0	642.1	0.6	736.5	742.6	0.8	NA	857.3	NM
PAT	21.7	20.9	-3.6	24.2	23.7	-2.0	NA	27.6	NM


Source: Company, Emkay Research; Note: NM = Not meaningful

Story in charts

Exhibit 5: With steady demand, ULIP commands 34% share




Source: Company, Emkay Research




Source: Company, Emkay Research

Exhibit 9: 61st month persistency witnesses YoY and sequential improvement




Source: Company, Emkay Research

Exhibit 6: The Banca channel's contribution is stable




Source: Company, Emkay Research

Exhibit 8: VNB margin improves sequentially to 25.6%




Source: Company, Emkay Research

Exhibit 10: Expense ratio witnesses sequential improvement




Source: Company, Emkay Research

Exhibit 11: Protection contributes to 11.2% of APE




Source: Company, Emkay Research

Exhibit 13: We expect HDFC Life to deliver 15-16% APE growth over FY26-28E




Source: Company, Emkay Research

Exhibit 15: We expect HDFC life to deliver EV of Rs857bn by FY28E




Source: Company, Emkay Research

Exhibit 12: Retail Protection witnesses 28% QoQ growth during Q4FY25




Source: Company, Emkay Research

Exhibit 14: VNB margins to see gradual improvement over FY26-28E



Source: Company, Emkay Research

Exhibit 16: We expect cost ratios to be largely stable going



Source: Company, Emkay Research

Earnings conference call highlights

- The company has doubled all the key metrics between FY21 and FY25 and, going forward, the management remains confident of doubling the key metrics over coming four years too.
- ULIP demand remained strong during Q4FY25, despite the volatile markets. The management expects traditional products to perform well led by the lower interest rate scenario and uncertainty in equity markets. The Credit Protection business saw a slowdown, on account of the slowdown in MFI disbursals.
- While the company maintained its counter share at the HDFC Bank channel, HDFC Banks's contribution to HDFC Life's APE stood at 47%.
- The management expects moderate growth in H1FY26, driven by a high base and continued slowdown in MFI disbursals; however, H2FY26 should see growth even out.
- Protection has grown 25% in recent years; the management expects growth in the protection business next year as well and to log higher than company-level growth.
- The management mentioned that Banca is a considerably important channel for achieving 'Insurance for all by 2047'. While the banca channel has 6-10x more branches than the insurance sector, letting go of these touch points would reflect poorly on the industry.
- Key areas of investment in the Agency and Proprietary channels include a combination of Branches, Training, People, PayScale, and Technology driving an improvement in the quality of people in the Agency channel.
- While margins will remain range bound, any uplift will be invested back into the business toward distribution and technology.
- Over four years (FY21-25), the company has almost doubled the key metrics (Renewal Premium, Annuity, Protection, AUM, EV) the management remains committed to delivering these numbers ahead too, over 4-4.5 years. Margins should start moving upward, with the investments and tech transformation now behind.
- The company is mulling taking forward the mix of ULIP in HDFC Bank, and is working on increasing the sum assured and adding more riders and protection benefits which will help improve margins.
- Par margins might be lower than non-par, but margin delta has not been as high in the past given the longer term of par products.
- Project Inspire is a long-term project. The objective is to create a specific moat for the company, driven by seamless integration with partners. With better integration, the company will be able to handle higher volumes and enhance the experience for channel partners as well.
- The company will see retirement of the first tranche of debt in the next few months, and the management will take a call on whether to renew it.
- While the company saw robust growth in H1FY25 (a high base for H1FY26), dimensions could be different in FY26 given macro uncertainties. VNB growth will not be as back ended as APE growth for FY26.

HDFC Life Insurance: Standalone Financials and Valuations

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Gross premium	630,765	710,449	823,820	956,744	1,112,486
Net premium	619,592	696,161	807,252	937,503	1,090,113
Investment income	383,543	259,453	276,529	316,681	363,834
Other income	4,608	3,834	1,505	1,405	1,305
Total revenue	1,007,743	959,448	1,085,286	1,255,589	1,455,253
Commission expense	52,563	78,353	90,856	104,513	120,359
Operating expense	69,011	62,218	71,121	81,734	94,036
Benefits paid (net)	396,965	393,459	453,540	518,468	594,675
Change in reserves	484,194	415,156	456,958	536,349	630,177
Total expenses	999,991	949,019	1,071,328	1,239,731	1,437,697
Surplus/Deficit	7,751	10,430	13,958	15,858	17,555
Trf from policyholders acct	7,991	9,968	13,340	15,156	16,778
Shareholders' results	7,647	8,693	8,404	9,541	12,012
PBT	15,638	18,661	21,745	24,697	28,790
Extraordinary items	-	-	-	-	-
Tax expense	(50)	640	870	988	1,152
Minority interest	-	-	-	-	-
Income from JV/Associates	-	-	-	-	-
Reported PAT	15,689	18,021	20,875	23,709	27,639
PAT growth (%)	15.3	14.9	15.8	13.6	16.6
Adjusted PAT	15,689	18,021	20,875	23,709	27,639
Diluted EPS (Rs)	7.3	8.4	9.8	11.1	12.9
Diluted EPS growth (%)	15.3	14.9	15.8	13.6	16.6
DPS (Rs)	1.9	2.0	2.4	2.8	3.2
Dividend payout (%)	26.0	23.9	25.0	25.0	25.0
Effective tax rate (%)	(0.3)	3.4	4.0	4.0	4.0
Shares outstanding (mn)	2,151	2,153	2,153	2,153	2,153

Source: Company, Emkay Research

balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	21,509	21,530	21,530	21,530	21,530
Reserves & Surplus	125,008	139,720	155,376	173,158	193,887
Net worth	146,517	161,256	176,906	194,688	215,417
Borrowings	9,500	29,500	29,500	29,500	29,500
Policy liabilities	1,753,488	2,107,778	2,545,366	3,067,151	3,688,111
Provision for linked liab	921,145	977,434	1,109,522	1,262,615	1,440,177
FFA	12,115	12,576	13,194	13,896	14,673
Current liab and provision	86,665	94,842	112,301	132,712	156,709
Total liabilities & Equity	2,937,293	3,395,342	3,868,568	4,423,401	5,075,085
Shareholders' Investment	148,819	183,863	201,707	221,982	245,617
Policyholder Investment	1,817,966	2,162,671	2,472,272	2,835,663	3,262,624
Assets to cover linked liab.	955,416	1,016,282	1,161,769	1,332,534	1,533,171
Current assets	79,739	98,724	112,484	128,617	147,565
Total Assets	2,937,293	3,395,342	3,868,568	4,423,401	5,075,085
BV/Share (INR)	68.1	74.9	82.2	90.4	100.1
EV/share (INR)	220.7	257.5	298.2	344.9	398.2
EVOP/share (INR)	32.4	37.1	42.9	49.1	56.3
Embedded value	474,690	554,310	642,086	742,582	857,331
ANW	145,300	162,830	178,480	196,262	216,991
VIF	329,390	391,480	463,606	546,320	640,340
VIF share in EV (%)	69.4	70.6	72.2	73.6	74.7
Total AUM	2,922,201	3,362,815	3,835,748	4,390,179	5,041,413
Investment yield (%)	14.8	8.6	8.0	8.0	8.1
Yield on PH funds (%)	23.4	13.0	11.9	11.9	11.9
Yield on SH funds (%)	7.2	6.8	6.3	6.3	6.8

Balance Sheet

Miscellaneous Metrics					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
APE	132,910	154,790	178,391	206,410	238,885
VNB	35,010	39,620	45,708	53,407	62,300
VNB margin (%)	26.3	25.6	25.6	25.9	26.1
APE growth (%)	(0.3)	16.5	15.2	15.7	15.7
VNB growth (%)	(4.7)	13.2	15.4	16.8	16.7
Operating ratios (%)					
NB commission/APE	35.6	41.7	41.3	41.1	40.9
Commissions/TWRP	11.3	14.9	15.1	15.1	15.1
Total exp ratio/TWRP	26.2	26.7	26.8	26.9	27.0
Conservation ratio	84.1	84.6	85.0	85.0	85.0
Solvency ratio	187.0	194.0	192.0	190.0	190.0
ROE	11.4	11.7	12.3	12.8	13.5
Historical metrics					
APE mix (%)	FY24	FY25	FY26E	FY27E	FY28E
A. Retail protection	4.4	4.8	0	0	0
B. Group protection	8.9	6.4	0	0	0
C. Savings - individual	0	0	0	0	0
Par	20.3	17.3	Ō	0	0
Non-Par	32.4	33.3	0	0	0
ULIP	30.8	34.4	Ō	0	0
D. Group Savings	3.2	4.0	0	0	0
Persistency ratios (%)	-	-	-	-	-
13th Month	87.0	87.0	0	0	0
49th Month	70.0	70.0	0	0	0

Source: Company, Emkay Research

Valuation & key ratios	•				
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	98.0	85.3	73.7	64.8	55.6
P/B (x)	10.6	9.6	8.8	8.0	7.2
P/EV (x)	3.3	2.8	2.4	2.1	1.8
P/EVOP (x)	22.2	19.4	16.8	14.7	12.8
Implied P/VNB (x)	30.7	25.1	19.9	15.1	11.1
Dividend yield (%)	0.3	0.3	0.3	0.4	0.4
EV account and RoEV					
Opening EV	395,280	474,690	554,310	642,086	742,582
Premium unwind	32,400	38,400	44,287	50,015	56,358
VNB	35,010	39,620	45,708	53,407	62,300
Operating variance	1,800	1,200	1,500	1,501	1,501
EVOP	69,210	79,220	91,495	104,923	120,159
Investment variance	13,500	3,600	1,500	1,500	1,500
Capital movement	(3,300)	(3,200)	(5,219)	(5,927)	(6,910)
Other changes	0	0	0	0	0
Closing EV	474,690	554,310	642,086	742,582	857,331
Change in EV	79,410	79,620	87,776	100,496	114,749
RoEV (%)	17.5	16.7	16.5	16.3	16.2
Operating RoEV (%)	17.5	16.7	16.5	16.3	16.2
EVOP growth (%)	6.6	14.5	15.5	14.7	14.5
EV growth (%)	20.1	16.8	15.8	15.7	15.5
Core operating RoEV (%)	17.5	16.7	16.5	16.3	16.2
Unwind rate (%)	8.2	8.1	8.0	7.8	7.6
VNB-to-opening EV (%)	8.9	8.3	8.2	8.3	8.4

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
03-Apr-25	693	775	Buy	Avinash Singh
12-Feb-25	629	775	Buy	Avinash Singh
16-Jan-25	641	775	Buy	Avinash Singh
12-Jan-25	609	775	Buy	Avinash Singh
16-Dec-24	635	775	Buy	Avinash Singh
16-Oct-24	727	825	Buy	Avinash Singh
13-Oct-24	724	825	Buy	Avinash Singh
04-Oct-24	709	825	Buy	Avinash Singh
09-Sep-24	736	750	Buy	Avinash Singh
15-Aug-24	686	750	Buy	Avinash Singh
16-Jul-24	647	750	Buy	Avinash Singh
04-Jul-24	604	725	Buy	Avinash Singh
10-Jun-24	569	725	Buy	Avinash Singh
05-Jun-24	552	725	Buy	Avinash Singh
01-Jun-24	550	725	Buy	Avinash Singh
10-May-24	549	725	Buy	Avinash Singh
19-Apr-24	602	725	Buy	Avinash Singh
03-Apr-24	624	700	Add	Avinash Singh
26-Mar-24	627	700	Add	Avinash Singh
09-Mar-24	622	700	Add	Avinash Singh
07-Mar-24	622	700	Add	Avinash Singh
13-Jan-24	638	725	Add	Avinash Singh
09-Jan-24	641	750	Add	Avinash Singh
07-Jan-24	647	750	Add	Avinash Singh
28-Dec-23	648	740	Add	Avinash Singh
18-Dec-23	672	740	Add	Avinash Singh
07-Dec-23	678	740	Add	Avinash Singh
30-Nov-23	691	740	Add	Avinash Singh
30-Nov-23	691	740	Buy	Avinash Singh
07-Nov-23	622	740	Buy	Avinash Singh
14-Oct-23	625	740	Buy	Avinash Singh
09-Oct-23	615	740	Buy	Avinash Singh
04-Oct-23	626	740	Buy	Avinash Singh
08-Sep-23	657	740	Buy	Avinash Singh
21-Aug-23	625	740	Buy	Avinash Singh
09-Aug-23	646	740	Buy	Avinash Singh
22-Jul-23	647	740	Buy	Avinash Singh
09-Jul-23	658	740	Buy	Avinash Singh
10-Jun-23	582	650	Buy	Avinash Singh
01-Jun-23	582	650	Buy	Avinash Singh
16-May-23	560	650	Buy	Avinash Singh
27-Apr-23	518	650	Buy	Avinash Singh
23-Apr-23	513	650	Buy	Avinash Singh
21-Apr-23	513	550	Hold	Avinash Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SFBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of April 18, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of April 18, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the April 18, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

	,		
Ratings	Expected Return within the next 12-18 months.		
BUY	>15% upside		
ADD	5-15% upside		
REDUCE	5% upside to 15% downside		
SELL	<15% downside		

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marq, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

Seshadri by Seshadri Kumar Sen Date: 2025.04.18 02:35:24 +05'30'